U.S. markets closed
  • S&P 500

    4,443.11
    -12.37 (-0.28%)
     
  • Dow 30

    34,869.37
    +71.37 (+0.21%)
     
  • Nasdaq

    14,969.97
    -77.73 (-0.52%)
     
  • Russell 2000

    2,281.26
    +33.18 (+1.48%)
     
  • Crude Oil

    75.49
    +1.51 (+2.04%)
     
  • Gold

    1,750.00
    -1.70 (-0.10%)
     
  • Silver

    22.64
    +0.22 (+0.96%)
     
  • EUR/USD

    1.1701
    -0.0016 (-0.14%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • GBP/USD

    1.3707
    +0.0026 (+0.19%)
     
  • USD/JPY

    111.0000
    +0.3150 (+0.28%)
     
  • BTC-USD

    42,883.99
    -453.10 (-1.05%)
     
  • CMC Crypto 200

    1,061.12
    -40.40 (-3.67%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors of Class Action and Deadline: November 24, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bmrn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would not approve the Biologics License Application ("BLA") for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/bmrn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in BioMarin you have until November 24, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/618235/BMRN-Final-Deadline-Bronstein-Gewirtz-Grossman-LLC-Reminds-BioMarin-Pharmaceutical-Inc-Investors-of-Class-Action-and-Deadline-November-24-2020